Cingulate Nears FDA Verdict on ADHD Drug Amid Manufacturing Hurdles

KANSAS CITY, Kan. – March 18, 2026 – Cingulate Inc. is moving into a decisive period as it awaits a landmark decision from the U.S. Food and Drug Administration (FDA) on its novel once-daily ADHD medication, CTx-1301. With a target action date of May 31, 2026, the biopharmaceutical company is on the cusp of potentially launching a drug designed to address significant gaps in the massive ADHD treatment market. However, recent FDA requests for additional manufacturing information introduce a critical variable into the final stretch, underscoring the high-stakes pressure cooker of late-stage drug development.

The company announced its year-end 2025 financial results alongside a series of major operational milestones, including strengthened patent protection in the U.S. and Europe and the closing of a crucial $12 million financing round. These developments paint a picture of a company methodically preparing for a commercial launch, even as it navigates the final, and often unpredictable, stages of regulatory review.

A New Approach to All-Day ADHD Control

The market for Attention-Deficit/Hyperactivity Disorder is a multi-billion dollar industry, with an estimated 100 million annual prescriptions in the United States alone. Yet, for many of the more than 20 million diagnosed patients, treatment remains a challenge. A common complaint with existing extended-release stimulants is that their effects can wane by the afternoon, leading to a return of symptoms and the need for inconvenient booster doses.

Cingulate aims to solve this with CTx-1301 (dexmethylphenidate HCl) and its proprietary Precision Timed Release™ (PTR™) drug delivery platform. The technology embeds three separate doses of medication within a single tablet, each designed to release at precise, pre-defined intervals throughout the day.

“Cingulate is proud to announce that CTx-1301 has strengthened its patent estate,” CEO Shane J. Schaffer stated in the company’s recent press release. “We have demonstrated that CTx-1301 utilizing the PTR™ Platform does something meaningfully different in the treatment of ADHD.”

The goal is to provide a rapid onset of symptom control in the morning followed by sustained efficacy for a patient's “entire active day.” Phase 3 clinical trials supported this design, demonstrating large effect sizes and consistent benefits in both children and adults. This “true once-daily” dosing profile is the core of Cingulate's value proposition, promising improved convenience and adherence for patients and their families.

The Final Regulatory Gauntlet

After submitting its New Drug Application (NDA) in July 2025, Cingulate received a significant validation when the FDA accepted it for review in October, assigning the May 31, 2026, Prescription Drug User Fee Act (PDUFA) target date. However, the path to approval is rarely without obstacles.

The company disclosed that the FDA has requested additional information related to Chemistry, Manufacturing, and Controls (CMC) for CTx-1301. While Cingulate emphasized that these requests do not concern the drug's clinical safety or efficacy data, CMC queries are a serious matter. They can cover everything from the stability of the final product to the validation of manufacturing processes. Depending on the complexity of the FDA's questions and the time needed to provide satisfactory answers, such requests have the potential to extend the PDUFA review timeline.

Cingulate has been proactive in its manufacturing preparations. It previously announced the successful completion of twelve registration batches required for the NDA submission and, in September 2025, entered into an exclusive commercial supply agreement with Bend Bio Sciences to manufacture CTx-1301 in the U.S. through 2028. This partnership is designed to ensure manufacturing security and scale-up capacity, but the company must first satisfy all of the agency's current inquiries.

Fortifying for a Commercial Future

While navigating the FDA review, Cingulate has been aggressively building its commercial foundation. The company recently shored up its intellectual property, receiving a Notice of Allowance for a U.S. patent and the granting of a European patent. Both provide protection for CTx-1301 through May 2042, creating a long runway for market exclusivity should the drug be approved.

On the commercial front, the appointment of Bryan Downey as Chief Commercial Officer in November signaled a clear shift in focus toward launch readiness. Downey brings decades of experience from leadership roles at Sanofi, Jubilant Pharma, and Alfasigma USA. His team is advancing market access strategies and engaging with payers to ensure CTx-1301 can achieve broad coverage upon launch. The company has also partnered with Indegene, a life sciences commercialization firm, using a flexible variable-cost model to align spending with growth milestones.

The Financial Countdown

For any pre-revenue biopharmaceutical company, the balance sheet is as critical as the clinical data. Cingulate reported a net loss of $22.4 million for 2025, up from $16.6 million in 2024. The increase was driven largely by a near-doubling of general and administrative expenses to $10.2 million as the company ramped up its pre-commercialization activities.

As of December 31, 2025, the company held approximately $11.0 million in cash. This figure was bolstered in February 2026 by the closing of a $12 million private investment in public equity (PIPE) financing, a critical infusion of capital led by Falcon Creek Capital Advisor LLC.

Cingulate projects its current cash reserves will fund operations into the late fourth quarter of 2026. This financial runway puts immense pressure on the upcoming PDUFA date. A timely approval and successful launch are essential to begin generating revenue and secure the company's long-term financial stability. The next few months will reveal whether Cingulate’s innovative timed-release technology can clear its final regulatory and manufacturing hurdles to reach the millions of patients it aims to help.